attralus-logo.png
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology
October 02, 2023 07:00 ET | Attralus, Inc
Attralus announced eight data presentations related to the use of 124I-evuzamitide (AT-01), the company's pan-amyloid binding imaging agent, at ASNC 2023.